Erythropoietin therapy in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 20, Issue SUPPL. 2, 2000, Pages

  Morris, Alice T ^a   Ronco, Claudio ^a,b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Anemia; Erythropoietin; RHuEPO

Indexed keywords

ASCORBIC ACID; CARNITINE; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ADJUVANT THERAPY; ANEMIA; APOPTOSIS; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DOSE RESPONSE; DYSERYTHROPOIESIS; ERYTHROCYTE LIFESPAN; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOLYSIS; HUMAN; HYPERTENSION; IRON DEFICIENCY; IRON OVERLOAD; IRON THERAPY; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; UREMIA;

EID: 0034045703     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002002s33     Document Type: Article

References (20)

1. Stojimirovic B, Grujic - Adanja G. The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia. Srp Arh Celok Lek 1997; 125:163-7.
2. Joske RA, McAlister JM, Prankerd TAJ. Isotope investigations of red cell production and destruction in chronic renal disease [Abstract]. Clin Sci 1956; 15:511.
3. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18(54):7719-30.
4. National Kidney Foundation Dialysis Outcomes Quality Initiative. Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 1997; 30(Suppl 3):S192-240.
5. Nissenson AR. Optimal hematocrit in patients on dialysis therapy. Am J Kidney Dis 1998; 32(Suppl 4):S142-6.
6. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39:155-63.
7. Eshbach J, Glenny R, Robertson T, Guthrie M, Rader B, Evans R, et al. Normalizing the hematocrit (Hct) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe [Abstract]. J Am Soc Nephrol 1993; 4:425.
8. Evans RW, Radar B, Manninen DL, and the Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263:825-30.
9. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43:184-8.
10. Eschbach JW, Abdulhadi MH, Brown JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Ann Intern Med 1989; 111:992-1000.
11. Paszkowska M, Jezynska A, Krol M, Rokicka -Piotrowicz M, Kuratowska Z. Zinc protoporphyrin (ZZP) in diagnosis of anemia. Pol Arch Med Wewn 1997; 12:520-6.
12. Hastka J, Lasserre JJ, Schwarzbeck A, Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 1994; 40:768-73.
13. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13:2867-72.
14. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999; 55:2477-86.
15. Paganini EP. Overview of anemia associated with renal disease: Primary and secondary mechanisms. Semin Nephrol 1989; (1 Suppl 1):3-8.
16. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821-8.
17. Metry G, Wikström B, Valind S, Sandhagen B, Linde T, Beshara S, et al. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 1999; 10:854-63.
18. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal versus low hematocrit values in hemodialysis patients with cardiac disease. N Engl J Med 1998; 339:584-90.
19. Burkart JM, Freedman BI, Rocco MV. The effect of increasing hematocrit on peritoneal transport kinetics. J Am Soc Nephrol 1994; 4:1726-32.
20. Gandolfo C, Battista G, Viglino G, Cavalli P. Hematocrit has no effect on peritoneal transport indices. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1995; 11:41-4.